Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Olli Moisio; Jenni Virta; Emrah Yatkin; Heidi Liljenbäck; Senthil Palani; Riikka Viitanen; Maxwell W.G. Miner; Vesa Oikonen; Tuula Tolvanen; Danielle J. Vugts; Pekka Taimen; Xiang-Guo Li; Maija Hollmén; Sirpa Jalkanen; Anne Roivainen

doi:10.2967/jnumed.122.264725

Research ArticleBasic Science Investigation

Open Access

Preclinical Evaluation of ⁸⁹Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Olli Moisio, Jenni Virta, Emrah Yatkin, Heidi Liljenbäck, Senthil Palani, Riikka Viitanen, Maxwell W.G. Miner, Vesa Oikonen, Tuula Tolvanen, Danielle J. Vugts, Pekka Taimen, Xiang-Guo Li, Maija Hollmén, Sirpa Jalkanen and Anne Roivainen

Journal of Nuclear Medicine April 2023, 64 (4) 555-560; DOI: https://doi.org/10.2967/jnumed.122.264725

Olli Moisio

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jenni Virta

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Emrah Yatkin

2Central Animal Laboratory, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heidi Liljenbäck

1Turku PET Centre, University of Turku, Turku, Finland;

3Turku Center for Disease Modeling, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Senthil Palani

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Riikka Viitanen

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maxwell W.G. Miner

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vesa Oikonen

1Turku PET Centre, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tuula Tolvanen

4Turku PET Centre, Turku University Hospital, Turku, Finland;

5Department of Medical Physics, Turku University Hospital, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Danielle J. Vugts

6Department of Radiology and Nuclear Medicine, Amsterdam UMC, VU University, Amsterdam, The Netherlands;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pekka Taimen

7Institute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland;

8InFLAMES Research Flagship Center, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Xiang-Guo Li

1Turku PET Centre, University of Turku, Turku, Finland;

8InFLAMES Research Flagship Center, University of Turku, Turku, Finland;

9Department of Chemistry, University of Turku, Turku, Finland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maija Hollmén

8InFLAMES Research Flagship Center, University of Turku, Turku, Finland;

10MediCity Research Laboratory, University of Turku, Turku, Finland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sirpa Jalkanen

8InFLAMES Research Flagship Center, University of Turku, Turku, Finland;

10MediCity Research Laboratory, University of Turku, Turku, Finland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anne Roivainen

1Turku PET Centre, University of Turku, Turku, Finland;

3Turku Center for Disease Modeling, University of Turku, Turku, Finland;

4Turku PET Centre, Turku University Hospital, Turku, Finland;

8InFLAMES Research Flagship Center, University of Turku, Turku, Finland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 4

April 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Preclinical Evaluation of ⁸⁹Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Journal of Nuclear Medicine Apr 2023, 64 (4) 555-560; DOI: 10.2967/jnumed.122.264725

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Preclinical Evaluation of ⁸⁹Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Journal of Nuclear Medicine Apr 2023, 64 (4) 555-560; DOI: 10.2967/jnumed.122.264725

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

bexmarilimab
CLEVER-1
PET/CT
renal fibrosis
whole-body distribution
89Zr

Main menu

User menu

Search

Preclinical Evaluation of ⁸⁹Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords